CLAIMS:

What is claimed is:

1. A method to measure a gene expression value for a portfolio of genes in a subject, comprising[[;]][[:]]

detecting the gene expression level of the portfolio of genes within said sample, said portfolio of genes identified by at least one of a set of SEQ ID NO. 1 to SEQ ID NO. 61 and combination thereof; and

normalizing the gene expression level of the portfolio of genes using at least one of a house keeping gene, a normal sample and a sample from the subject.

2. The method of claim 1, further comprising:

performing a computer implemented statistical analysis on the level of gene expression level for the portfolio of genes, wherein the statistically significant value representing collectively the level of gene expression value for the portfolio of genes indicates that said subject having at least one of a cancer, progression of cancer, effect of treatment for cancer and location of cancer.

3. The method of claim 1, wherein the portfolio of genes for breast cancer are SEQ ID. 22- 43.

4. The method of claim 1, wherein the portfolio of genes for leukemia are of SEQ.ID. 1- 21.

5. The method of claim 1, wherein the portfolio of genes for brain cancer are SEQ ID. 44- 61.

6. The method of claim 1, wherein the house keeping gene is GAPDH.

7. The method of claim 1, wherein the sample is at least one of biopsy sample, fine needle aspirate, parafilm embedded samples, tumor tissue, immune cells, whole blood, saliva, urine, synovial fluid, bone marrow, cerebrospinal fluid, vaginal mucus, cervical mucus, nasal secretions, sputum, semen, amniotic fluid, bronchoalveolar lavage fluid, and other cellular exudates from a patient having cancer.

8. A method of diagnosing cancer, comprising:

identifying differential modulation of each gene relative to the expression of the same genes as the control subject in a portfolio of genes selected from the group for at least one of Leukemia, Breast and Brain cancer, wherein the portfolio of genes is at least one of Seq. ID. No. 001 to Seq ID. No. 061.

9. The method of claim 8, wherein the portfolio of genes for breast cancer are SEQ ID. 22- 43.

10. The method of claim 8, wherein the portfolio of genes for leukemia are of SEQ.ID. 1-21.

11. The method of claim 8, wherein the portfolio of genes for brain cancer are SEQ ID. 44- 61.

12. The method of claim 8, further comprising:

subjecting RNA extracted from a breast tissue obtained from the patient to gene expression analysis;

determining the expression level of one or more genes selected from the breast cancer genes, wherein the expression level is normalized against a control gene and in a breast cancer reference tissue set; and

storing the data and sharing it with the stake holders such as physicians, insurance companies and hospitals.

13. A kit, comprising:

a component for cDNA preparation;

a component for RT-PCR preparation;

an oligopeptide sequence for portfolio of genes identified by at least one of a set of SEQ ID NO. 1 to SEQ ID NO. 61 and combination thereof; and a reagent, and a buffer in suitable packaging, wherein the reagent comprises of the RNAse inhibitor, TRIZOL™ reagent, ethanol, dNTPs, Reverse Transcriptase enzyme, stabilizing buffer solutions, DNA polymerases, SYBER green dNTPs and magnesium chloride.